C4 Therapeutics Inc. (CCCC)
C4 Therapeutics Statistics
Share Statistics
C4 Therapeutics has 71.01M shares outstanding. The number of shares has increased by 3.17% in one year.
| Shares Outstanding | 71.01M |
| Shares Change (YoY) | 3.17% |
| Shares Change (QoQ) | 0.57% |
| Owned by Institutions (%) | 92.49% |
| Shares Floating | 56.72M |
| Failed to Deliver (FTD) Shares | 2.61K |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 7.76M, so 11% of the outstanding shares have been sold short.
| Short Interest | 7.76M |
| Short % of Shares Out | 11% |
| Short % of Float | 13.32% |
| Short Ratio (days to cover) | 9.66 |
Valuation Ratios
The PE ratio is -2.37 and the forward PE ratio is null. C4 Therapeutics's PEG ratio is 0.06.
| PE Ratio | -2.37 |
| Forward PE | n/a |
| PS Ratio | 7.02 |
| Forward PS | 3.2 |
| PB Ratio | 1.16 |
| P/FCF Ratio | -3.82 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for C4 Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.71, with a Debt / Equity ratio of 0.3.
| Current Ratio | 5.71 |
| Quick Ratio | 5.71 |
| Debt / Equity | 0.3 |
| Debt / EBITDA | -0.64 |
| Debt / FCF | -1.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $323.49K |
| Profits Per Employee | $-957.42K |
| Employee Count | 110 |
| Asset Turnover | 0.1 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 131K |
| Effective Tax Rate | -0.12% |
Stock Price Statistics
The stock price has increased by -74.36% in the last 52 weeks. The beta is 3.12, so C4 Therapeutics's price volatility has been higher than the market average.
| Beta | 3.12 |
| 52-Week Price Change | -74.36% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 4.41 |
| Relative Strength Index (RSI) | 49.28 |
| Average Volume (20 Days) | 1.38M |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of 35.58M and earned -105.32M in profits. Earnings per share was -1.52.
| Revenue | 35.58M |
| Gross Profit | 35.58M |
| Operating Income | -119.61M |
| Net Income | -105.32M |
| EBITDA | -103.37M |
| EBIT | -105.19M |
| Earnings Per Share (EPS) | -1.52 |
Balance Sheet
The company has 55.5M in cash and 65.76M in debt, giving a net cash position of -10.26M.
| Cash & Cash Equivalents | 55.5M |
| Total Debt | 65.76M |
| Net Cash | -10.26M |
| Retained Earnings | -633.7M |
| Total Assets | 349.6M |
| Working Capital | 212.59M |
Cash Flow
In the last 12 months, operating cash flow was -65.16M and capital expenditures -180K, giving a free cash flow of -65.34M.
| Operating Cash Flow | -65.16M |
| Capital Expenditures | -180K |
| Free Cash Flow | -65.34M |
| FCF Per Share | -0.94 |
Margins
Gross margin is 100%, with operating and profit margins of -336.15% and -295.96%.
| Gross Margin | 100% |
| Operating Margin | -336.15% |
| Pretax Margin | -295.6% |
| Profit Margin | -295.96% |
| EBITDA Margin | -290.49% |
| EBIT Margin | -336.15% |
| FCF Margin | -183.61% |
Dividends & Yields
CCCC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CCCC is $13, which is 712.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $13 |
| Price Target Difference | 712.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -2.2 |
| Piotroski F-Score | 4 |